Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Surgery for Distant Melanoma Metastasis

Surgery for Distant Melanoma Metastasis REVIEW ARTICLE Anna M. Leung, MD, Danielle M. Hari, MD, and Donald L. Morton, MD Systemic Treatment Options Abstract: Traditionally, distant metastatic melanoma has a poor prognosis Currently, there is no ‘‘gold standard’’ for treatment of stage owing to lack of efficacious, U.S. Food and Drug AdministrationYapproved IV melanoma. Surgical therapy for stage IV disease remains systemic therapy and the limited use of surgical resection as a thera- controversial. The National Comprehensive Cancer Network peutic option. More recently, new biological therapies such as vemur- guidelines for first- and second-line systemic therapy for stage IV afenib (Zelboraf ) and ipilimumab (Yervoy) have shown strong promise melanoma are unclear about the role of surgery versus systemic and dramatically improved the landscape of stage IV melanoma ther- 2,3 therapy. Unfortunately, systemic therapies are traditionally as- apy. Although there are numerous single-institution studies advocating sociated with variable response rates, limited impact on survival, the role for therapeutic surgical intervention, many remain skeptical of toxic adverse effects, and frequent lack of durable responses. nonpalliative surgery for metastatic melanoma. Surgical resection of The introduction of several new therapies in 2011 has dra- advanced melanoma has been proven to be effective as long as all dis- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Cancer Journal Wolters Kluwer Health

Surgery for Distant Melanoma Metastasis

Morton, Donald L.
The Cancer Journal , Volume 18 (2) – Mar 1, 2012
Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/surgery-for-distant-melanoma-metastasis-hA4jwZ9r2M

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by Lippincott Williams & Wilkins
ISSN
1528-9117
eISSN
1540-336X
DOI
10.1097/PPO.0b013e31824bc981
pmid
22453019
Publisher site
See Article on Publisher Site

Abstract

REVIEW ARTICLE Anna M. Leung, MD, Danielle M. Hari, MD, and Donald L. Morton, MD Systemic Treatment Options Abstract: Traditionally, distant metastatic melanoma has a poor prognosis Currently, there is no ‘‘gold standard’’ for treatment of stage owing to lack of efficacious, U.S. Food and Drug AdministrationYapproved IV melanoma. Surgical therapy for stage IV disease remains systemic therapy and the limited use of surgical resection as a thera- controversial. The National Comprehensive Cancer Network peutic option. More recently, new biological therapies such as vemur- guidelines for first- and second-line systemic therapy for stage IV afenib (Zelboraf ) and ipilimumab (Yervoy) have shown strong promise melanoma are unclear about the role of surgery versus systemic and dramatically improved the landscape of stage IV melanoma ther- 2,3 therapy. Unfortunately, systemic therapies are traditionally as- apy. Although there are numerous single-institution studies advocating sociated with variable response rates, limited impact on survival, the role for therapeutic surgical intervention, many remain skeptical of toxic adverse effects, and frequent lack of durable responses. nonpalliative surgery for metastatic melanoma. Surgical resection of The introduction of several new therapies in 2011 has dra- advanced melanoma has been proven to be effective as long as all dis-

Journal

The Cancer Journal – Wolters Kluwer Health

Published: Mar 1, 2012

There are no references for this article.